These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25631301)

  • 21. Maintaining confidentiality of interim data to enhance trial integrity and credibility.
    Fleming TR; Sharples K; McCall J; Moore A; Rodgers A; Stewart R
    Clin Trials; 2008; 5(2):157-67. PubMed ID: 18375654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protecting the confidentiality of interim data: addressing current challenges.
    Fleming TR
    Clin Trials; 2015 Feb; 12(1):5-11. PubMed ID: 25475877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Data monitoring committee interim reports: We must get there soon!
    DeMets DL; Wittes J
    Clin Trials; 2022 Feb; 19(1):107-111. PubMed ID: 34693741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 34. Building a more connected DSMB: better integrating ethics review and safety monitoring.
    Eckstein L
    Account Res; 2015; 22(2):81-105. PubMed ID: 25397600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
    Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D
    PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.
    Ball G; Piller LB; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S2-4. PubMed ID: 21664987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    J Clin Oncol; 2005 Aug; 23(24):5831-6. PubMed ID: 16027441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility.
    Buhr KA; Downs M; Rhorer J; Bechhofer R; Wittes J
    Ther Innov Regul Sci; 2018 Jul; 52(4):459-468. PubMed ID: 29714543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.